# AOD-9604

> C-terminal hGH fragment (177–191) historically investigated for lipolysis.

- Class: Metabolic
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/aod-9604

## Overview

AOD-9604 is a 16-amino-acid synthetic peptide derived from the lipolytic C-terminal domain of human growth hormone. Reached Phase IIb obesity trials without meeting weight-loss endpoints; later repositioned to cartilage / joint research.

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the lipolytic C-terminal region (residues 177–191) of human growth hormone. It was designed to reproduce GH’s fat-metabolizing effect without the growth-promoting or glucose effects of the full hormone.

It advanced into Phase IIb obesity trials but did not meet its weight-loss endpoints, after which research interest shifted toward cartilage and joint applications. It is not FDA-approved as a therapeutic.

## Mechanism

Putative β3-adrenergic mediated lipolysis without GH receptor binding.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C78H123N23O23S2 |
| Molecular weight | 1815.1 Da |
| PubChem CID | [71300630](https://pubchem.ncbi.nlm.nih.gov/compound/71300630) |

## Research areas

Studied in: Obesity (historical), Cartilage repair.

Guides on this site:

- [Weight Loss & Metabolic Health](https://www.americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss.
- [Wound Healing & Tissue Repair](https://www.americanpeptide.com/research-areas/wound-healing): Regenerative peptides studied for soft-tissue, tendon, and vascular repair.

## Key research

- Lipolysis — the GH fragment studied for fat metabolism without GH-receptor binding.
- Obesity trials — reached Phase IIb but did not meet weight-loss endpoints.
- Cartilage repair — repositioned toward joint research.
- Mechanism — proposed β3-adrenergic-mediated lipolysis.
- Not FDA-approved — did not meet clinical endpoints for obesity.

## FAQs

### What is AOD-9604?

AOD-9604 is a fragment of human growth hormone (residues 177–191) studied for fat metabolism (lipolysis) without GH’s other effects.

### Did it work for weight loss?

It reached Phase IIb obesity trials but did not meet its weight-loss endpoints; research later shifted toward cartilage and joint applications.

### How does it differ from full GH?

It is designed to reproduce GH’s lipolytic effect without binding the GH receptor or driving growth and glucose effects.

### Is it approved?

No — it is not FDA-approved as a therapeutic. This page is a research and educational reference.

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/aod-9604
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.